Glykos Finland Oy

Suomen Punainen Risti Veripalvelu

Glykos Finland

Nestec S.a.

Upm-kymmene Corporation

Tero Satomaa

Markus Nuopponen

Jari Natunen

Juhani Saarinen

Heidi Anderson

Maria Blomqvist

Jari Helin

Taina Jaatinen

Johanna Nystedt

Filip S Ekholm

Anita Laitinen

Sari Tiitinen

Jukka Hiltunen

Lauri Paasonen

Annamari Heiskanen

Jarmo Laine

Ulla Impola

Anne Olonen

Noora Salovuori

Milla Mikkola

Jukka Partanen

Leena Valmu

Karl-Anders Karlsson

Anja Vilkman

Heidi Virtanen

Minna Tiittanen

Susann Teneberg

Sarl Tiitinen

Halina Miller-Podraza

Niamh Roche

Olli Aitio

Jonas Angström

Maan Abul-Milh

Hydrophilic linkers and their conjugates are disclosed. Formula (I) (II)

Hydrophilic linkers and conjugates thereof

The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composi-tion. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.

Conjugates of a glycoprotein or a glycan with a toxic payload

The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.

Glycoprotein-toxic payload conjugates

A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.

Saccharide derivative of a toxic payload and antibody conjugates thereof

The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Method for evaluating cell populations

The invention relates to a composition comprising a glycoprotein comprising the Fc domain of an antibody, or a fragment thereof, comprising an Asn (asparagine) residue and an oligosaccharide structure attached thereto, wherein said oligosaccharide structure has a structure according to formula I; and wherein at least 20% of the oligosaccharide structures attached to glycoprotein in the composition consist of oligosaccharide structures according to formula (I).

Glycoprotein

The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.

Carbohydrate profile compositions from human cells and methods for analysis and modification thereof

The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Enzymatical modification of cell glycosylation using serum albumin and divalent cations

The present invention reveals novel methods for producing novel carbohydrate compositions, glycomes, from animal tissues. The tissue substrate materials can be total tissue samples and fractionated tissue parts, or artificial models of tissues such as cultivated cell lines. The invention is further directed to the compositions and compositions produced by the methods according to the invention. The invention further represent methods for analysis of the glycomes, especially mass spectrometric methods.

Tissue carbohydrate compositions and analysis thereof

The invention relates to a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) cells on a lectin. The invention relates also to the use of a lectin in a method for culturing human embryonic stem cells (hESCs) and/or induced pluripotent stem (iPS) celts and a culture medium composition containing a lectin attached on the culturing plates.

Culture of cells

The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.

Tumor specific oligosaccharide epitopes and use thereof

The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.

Compounds and combinations

The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAc&#x3b1;3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method.

Growing community of inventors

Helsinki, Finland

Tero Satomaa